Market closed

Avita Therapeutics/$RCEL

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Avita Therapeutics

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Ticker

$RCEL
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Valencia, United States

Employees

207
Website
www.avitamedical.com

RCEL Metrics

BasicAdvanced
$233M
-
-$2.23
1.58
-

$233M

1.58

$18.93

$7.51

185K

3.729

3.206

373.158

373.158

-11.34%

-45.37%

-152.44%

3.778

18.91

19.87

-3.796

32.24%

67.05%

What the Analysts think about RCEL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Avita Therapeutics stock.

RCEL Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RCEL Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RCEL News

AllArticlesVideos
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish

Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish

Seeking Alpha·2 days ago
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini

AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini

Seeking Alpha·4 days ago
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals

Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals

Benzinga·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RCEL

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Avita Therapeutics stock?

Avita Therapeutics (RCEL) has a market cap of $233M as of January 15, 2025.

What is the P/E ratio for Avita Therapeutics stock?

The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of January 15, 2025.

Does Avita Therapeutics stock pay dividends?

No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Avita Therapeutics dividend payment date?

Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Avita Therapeutics?

Avita Therapeutics (RCEL) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.